Sera Labs offers 1,500 recombinant proteins

Published: 1-Jun-2010
Research & Development

Including cytokines, growth factors, chemokines, hormones, enzymes and viral antigens

Sera Laboratories International, a UK-based serum specialist, has developed more than 1,500 recombinant proteins for a variety of species including human, mouse, rat, porcine, bovine and chicken. The collection includes cytokines, growth factors, chemokines, hormones, enzymes and viral antigens.

Sera Lab’s recombinant proteins are mainly derived from bacterial systems and also include mammalian, yeast, insect and plant sources. All are rigorously tested to ensure excellent quality and biological activity.

With headquarters and storage in Haywards Heath, West Sussex and a cell culture research facility in France, Sera Lab offers a complete range of animal-based research products from a variety of origins. The company supplies laboratories in more than 30 countries worldwide, either directly or through distributors.

See more

You may also like

Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Read more
Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents

Trending Articles

  1. Why weight sorting should move earlier in OSD development Phillip Ruda explains how earlier weight intelligence can improve process understanding, reduce risk and accelerate learning cycles
  2. Orphan drug sales to exceed $400bn by 2032, Evaluate report finds Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Moving with speed and scale: innovative, material-sparing approaches to accelerate clinical development As early-stage drug development is often hindered by limited API supply, rising costs and tight timelines, material-sparing technologies are helping companies to progress faster with less
  4. Lonza completes transformation to pure-play CDMO with agreement to divest Capsules & Health Ingredients Sale of CHI business to Lone Star funds marks final step in Lonza’s strategic shift to a focused CDMO model
  5. Naobios and SGS partner to manufacture RSV challenge agent for vaccine trials Naobios and SGS have partnered to produce a cGMP respiratory syncytial virus challenge agent for Controlled Human Infection Model studies, supporting faster development of vaccines against Respiratory Syncytial Virus

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development

Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease

Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258

The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Drug Delivery

Palvella's QTORIN achieves positive Phase III results

Working in collaboration with MedPharm, the biopharma company announced positive topline results from its Phase 3 SELVA study of QTORIN rapamycin, paving the way for the company to prepare for commercial-scale manufacturing
Drug Delivery

New cancer drug delivery system boosts absorption of Paclitaxel

Researchers from Osaka Metropolitan University have developed a drug-delivery system that effectively delivers anticancer medication to cancerous tissues, potentially offering a solution for therapeutics that are difficult to absorb
Research & Development

3PBIOVIAN and Colombia's National Cancer Institute partner to develop first locally produced oncology biosimilar

The CDMO has signed an agreement with Colombia's Instituto Nacional de Cancerología to develop a biosimilar monoclonal antibody for an oncology indication, with technology transfer planned to enable domestic manufacturing
Subscribe now